Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

First positive opinion for coverage in “Early coverage of digital medical devices” (PECAN) framework

07 Aug 2023

A new framework, called the “Early coverage of digital medical devices” (PECAN) framework, was recently introduced. Its goal is to accelerate patient access to innovative digital medical devices (telemonitoring or therapeutical purposes) in the areas of high unmet need for a one-year non-renewable period. It will facilitate the access of innovative digital medical devices to the market, allowing operators to begin an operational deployment before obtaining regular reimbursement.

On July 31, 2023, the National Committee for the evaluation of medical devices and health technologies (CNEDiMTS) at the French National Authority for Health (HAS) published the first favorable opinion regarding the inclusion in the PECAN framework related to CUREETY TECHCARE, a medical telemonitoring solution from Cureety, which is used for medical telemonitoring of adult cancer patients under systemic treatment and/or treated with radiotherapy. 

See the details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.